started · updated
Medical guidelines and studies update cancer treatment standards
New medical guidelines and clinical study results are establishing updated standards for the treatment of cervical and prostate cancers.
The updated S3 guideline for cervical carcinoma defines a new therapy standard for recurrences and metastases. The recommendation includes platinum and taxane-based chemotherapy combined with Pembrolizumab, sometimes supplemented with Bevacizumab. This approach targets the PD-L1 protein, which is present in 90 percent of these tumors. Additionally, the guidelines suggest more conservative surgical options, such as simple hysterectomy or conization, rather than radical procedures.
In prostate cancer research, long-term data from the PEACE-1 study presented at the ESMO 2026 congress shows that adding Abiraterone to standard hormone therapy and chemotherapy significantly improves survival rates for men with metastatic hormone-sensitive prostate cancer. In a subgroup of 710 patients, the addition of Abiraterone and Prednison reduced the risk of death by 32 percent, increasing median survival from 4.6 years to 6.1 years. The benefits of this triple combination remained evident even after an eight-year observation period.
Entities
ESMO · Matthias Beckmann · Robert Koch Institute · University Hospital Düsseldorf · University Hospital Erlangen